Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ascrinvacumab + Erfonrilimab in Advanced Solid Tumors
NCT04984668Phase 2Recruiting
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- Nov 2021
- Primary completion
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ascrinvacumab in hepatocellular carcinoma (HCC), Gastric carcinoma (GC), gastroesophageal junction adenocarcinoma and 2 more, sponsored by Kintor Pharmaceutical Limited. Primary endpoints: Treatment-emergent adverse events, treatment-related AEs, serious adverse events, Dose Limiting Toxicities up to 2 years, Recommended Phase 2 Dose and 1 more. Started Nov 2021; status: recruiting.
02
Drugs
ascrinvacumab
03
Conditions
hepatocellular carcinoma (HCC)Gastric carcinoma (GC)gastroesophageal junction adenocarcinomaurothelial carcinoma (UC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04984668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984668.